JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
EVALUATION OF VISUAL ACUITY, MACULAR STATUS, AND SUBFOVEAL CHOROIDAL THICKNESS CHANGES AFTER CATARACT SURGERY IN EYES WITH DIABETIC RETINOPATHY.
Retina (Philadelphia, Pa.)
PUBLISHED: 08-12-2014
Show Abstract
Hide Abstract
Progression of diabetic macular edema has been reported as a common cause of poor visual acuity recovery after cataract surgery in patients with diabetes. Despite being responsible for the blood supply to the outer retina, the role of the choroidal layer in the pathogenesis of diabetic retinopathy (DR) is not yet understood. Our objective is to characterize macular and subfoveal choroidal thickness changes after cataract surgery in eyes with DR.
Related JoVE Video
Switch from intravitreal ranibizumab to bevacizumab for the treatment of neovascular age-related macular degeneration: clinical comparison.
Ophthalmologica
PUBLISHED: 04-26-2014
Show Abstract
Hide Abstract
To compare outcomes after switching from intravitreal ranibizumab to bevacizumab in neovascular age-related macular degeneration (AMD).
Related JoVE Video
[Evaluation of antiangiogenic treatment results in choroidal neovascularization related to pathological myopia].
Acta Med Port
PUBLISHED: 02-28-2014
Show Abstract
Hide Abstract
Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes.
Related JoVE Video
Anti-VEGF therapy in myopic choroidal neovascularization: long-term results.
Ophthalmologica
PUBLISHED: 02-01-2014
Show Abstract
Hide Abstract
To evaluate the medium- and long-term efficacy of anti-VEGF agents in the treatment of choroidal neovascularization secondary to pathologic myopia (mCNV).
Related JoVE Video
Immediate effect of intravitreal injection of bevacizumab on intraocular pressure.
Clin Ophthalmol
PUBLISHED: 01-01-2014
Show Abstract
Hide Abstract
To investigate the immediate effect of intravitreal injection of bevacizumab on intraocular pressure (IOP).
Related JoVE Video
Choroidal and macular thickness changes induced by cataract surgery.
Clin Ophthalmol
PUBLISHED: 12-16-2013
Show Abstract
Hide Abstract
The aim of this study was to evaluate the effect of uneventful phacoemulsification on the morphology and thickness of the macula, the submacular choroid, and the peripapillary choroid.
Related JoVE Video
Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
Br J Ophthalmol
PUBLISHED: 09-11-2013
Show Abstract
Hide Abstract
To report the visual outcome after 4-year follow-up in a series of highly myopic eyes with choroidal neovascularisation (CNV) treated with antivascular endothelial growth factor (anti-VEGF) drugs.
Related JoVE Video
Multimodal imaging of acquired vitelliform lesion diagnosed at pseudohypopyon stage.
Case Rep Ophthalmol Med
PUBLISHED: 03-12-2013
Show Abstract
Hide Abstract
Purpose. To present a case study of a monocular acquired vitelliform lesion, studied with multimodal fundus imaging (spectral-domain-optical coherence tomography, fundus autofluorescence, and fluorescein angiography) with a followup of three years. Case Report. An asymptomatic macular lesion was detected on a 64-year-old man. Fundus exam revealed a macular lesion with an apparent horizontal level associated with multiple round small whitish lesions, suggestive of cuticular drusen. He was studied with autofluorescence of the fundus (FAF), fluorescein angiography (FA), spectral domain-optical coherence tomography (SD-OCT), and electrooculogram. The findings were compatible with the diagnosis of acquired vitelliform lesion, associated with cuticular drusen. After one year, the visual acuity decreased to 20/50, without identifiable alterations of the FAF, FA, or SD-OCT. Three years later, fundoscopy and imaging showed an evolution to a state similar to vitelli disruptive phase of Best disease with an improvement of visual acuity to 20/25. We report the results of FAF, FA, and SD-OCT at this stage. Conclusion. Acquired vitelliform lesions associated with cuticular drusen can present as a pseudohypopyon lesion, and the evolution to the atrophic phase can be associated with an improvement of visual acuity.
Related JoVE Video
Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.
Acta Ophthalmol
PUBLISHED: 09-29-2011
Show Abstract
Hide Abstract
To evaluate the changes of vascular endothelial growth factor (VEGF) plasma levels after intravitreal injections of ranibizumab or bevacizumab in patients with exudative age-related macular degeneration (AMD).
Related JoVE Video
Spectral-domain optical coherence tomography features of acute syphilitic posterior placoid chorioretinitis: the role of autoimmune response in pathogenesis.
Case Rep Ophthalmol
PUBLISHED: 01-25-2011
Show Abstract
Hide Abstract
Syphilis is an infectious disease that can cause a wide variety of ocular signs. One of the rarest manifestations of ocular syphilis is acute syphilitic posterior placoid chorioretinitis (ASPPC). We report on the spectral-domain optical coherence tomography (SD-OCT) features of a case diagnosed with unilateral ASPPC.
Related JoVE Video
Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.
Retina (Philadelphia, Pa.)
PUBLISHED: 01-23-2010
Show Abstract
Hide Abstract
The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab after 12 months in the treatment of choroidal neovascularization secondary to pathologic myopia.
Related JoVE Video
Multiple effects of bevacizumab in angiogenesis: implications for its use in age-related macular degeneration.
Acta Ophthalmol
PUBLISHED: 11-07-2009
Show Abstract
Hide Abstract
This study aimed to elucidate the precise effects of bevacizumab in all steps in the neovascularization process in endothelial cells.
Related JoVE Video
Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study.
J. Cell. Biochem.
PUBLISHED: 10-28-2009
Show Abstract
Hide Abstract
Given its broad effects in endothelium, vascular endothelial growth factor (VEGF) represents the primary rate-limiting step of angiogenesis. Therefore, VEGF targeting therapies were soon developed. Bevacizumab and ranibizumab are two of these therapeutic agents already in clinical use. Bevacizumab was first used for cancer treatment, whereas ranibizumab was designed to target choroidal neovascularization, the main cause of blindness in age-related macular degeneration. The present study aims to compare the multiple effects of bevacizumab and ranibizumab in human microvascular endothelial cells (HMECs). HMEC cultures were established and treated during 24 h with the anti-VEGF agents within the intravitreal-established concentration range or excipients. Analyses of VEGF content in cell media and VEGF receptor-2 (VEGFR-2) expression in cell lysates were performed. No cell cytotoxicity (MTS assay) was found in anti-VEGF-treated cultures at any concentration. Apoptosis (TUNEL assay) was significantly increased and cell proliferation (BrdU assay), migration (transwell assay) and assembly into vascular structures were significantly reduced by incubation with both agents at the two doses used. These findings were accompanied by a strong decrease in VEGF release, and in phosphorylated VEGFR-2 and Akt expression for both agents at the clinical concentration. Interestingly, phosphorylated Erk was only significantly reduced upon bevacizumab treatment. In addition, proliferation was more affected by ranibizumab, whereas migration, capillary formation, and phosphorylated VEGFR2 expression were significantly reduced by bevacizumab as compared to ranibizumab. Therefore, although both agents presented anti-angiogenic actions, distinct effects were exerted by the two molecules in HMEC. These findings suggest that a careful confirmation of these effects in clinical settings is mandatory.
Related JoVE Video
Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.
Exp. Eye Res.
PUBLISHED: 01-13-2009
Show Abstract
Hide Abstract
Anti-VEGF therapy proved to be useful against several ocular pathological situations, including choroidal neovascularization and proliferative retinopathies. Ranibizumab (Ran), Pegaptanib (Peg) and Bevacizumab (Bev) are the pharmacological agents more frequently used in clinical practice by intravitreal injection. However, their exact effects on the angiogenic process have not been accurately established in a comparative study. The aim of the present study was to elucidate the precise effects of Ran, Peg and Bev on the multiple steps of the angiogenic process. Human umbilical vein endothelial cells (HUVEC) were incubated with each agent within the clinically established concentration range, or identical amounts of the excipients; cell cytotoxicity, proliferation, apoptosis, migration and vessel assembly were assessed. No cytotoxic effects were found for any of the agents studied at any concentration tested. At the clinical dose, cell proliferation was significantly reduced by Bev and Ran, whereas no difference was observed after Peg treatment. In addition, HUVEC apoptosis was effectively increased by Bev and Ran. Cell migration was reduced after incubation with every agent analyzed, though only reaching statistical significance upon Ran intravitreal dose. At clinical doses, capillary assembly was only affected by Bev. In agreement with these data, the active form of VEGF receptor-2 expression was decreased after incubation with Bev (to 66% of control values), Ran (78%) and Peg (86%) relative to controls. These findings indicate that these three agents display distinct effects on endothelial cells.
Related JoVE Video
A clear cell renal cell carcinoma inhibiting the response to intravitreal antivascular endothelial growth factor therapy in wet age-related macular disease.
Case Rep Ophthalmol
Show Abstract
Hide Abstract
Wet age-related macular degeneration (AMD) is an ocular disorder that can be successfully treated with intravitreal antivascular endothelial growth factor (VEGF) therapy. We report a case of incomplete response to intravitreal therapy associated with a clear cell renal cell carcinoma (ccRCC).
Related JoVE Video
Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting.
Clin Ophthalmol
Show Abstract
Hide Abstract
We compared the efficacy of intravitreal ranibizumab and bevacizumab for treating neovascular age-related macular degeneration using an on-demand regimen.
Related JoVE Video
Isolated foveal hypoplasia: tomographic, angiographic and autofluorescence patterns.
Case Rep Ophthalmol Med
Show Abstract
Hide Abstract
Purpose. To report clinical aspects, tomographic, angiographic, and autofluorescence patterns of two cases of isolated foveal hypoplasia. Methods. Foveal hypoplasia was found in a 23-year-old male patient and in a 64-year-old woman with impaired visual acuity of unknown etiology that remained unchanged for years. Results. In the first case, spectral-domain optical coherence tomography (SD-OCT) showed reduced foveal pit and continuity of inner retinal layers in the fovea. Photoreceptor layer had a normal thickness centrally. The foveal avascular zone (FAZ) was absent in the flourescein angiogram (FA). Fundus autofluorescence showed reduced foveal attenuation of autofluorescence. In the second patient, there was the same pattern in SD-OCT, with normal aspect in FA and only a slightly reduced foveal attenuation of autofluorescence. Conclusion. OCT, as a noninvasive and quick method, is helpful in the diagnosis of foveal hypoplasia. FA and fundus autofluorescence were less sensitive.
Related JoVE Video
Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity.
Case Rep Ophthalmol
Show Abstract
Hide Abstract
To report on 2 cases of aggressive posterior retinopathy of prematurity (ROP) treated with intravitreal ranibizumab (Lucentis(®)) and laser photocoagulation.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.